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A Role of the Bile Salt Receptor FXR in Atherosclerosis
Jurre Hageman, Hilde Herrema, Albert K. Groen, Folkert Kuipers
Abstract—This study reviews current insights into the role of bile salts and bile salt receptors on the progression and
regression of atherosclerosis. Bile salts have emerged as important modifiers of lipid and energy metabolism. At the
molecular level, bile salts regulate lipid and energy homeostasis mainly via the bile salt receptors FXR and TGR5.
Activation of FXR has been shown to improve plasma lipid profiles, whereas Fxr/ mice have increased plasma
triglyceride and very-low-density lipoprotein levels. Nevertheless, high-density lipoprotein cholesterol levels are
increased in these mice, suggesting that FXR has both anti- and proatherosclerotic properties. Interestingly, there is
increasing evidence for a role of FXR in “nonclassical” bile salt target tissues, eg, vasculature and macrophages. In these
tissues, FXR has been shown to influence vascular tension and regulate the unloading of cholesterol from foam cells,
respectively. Recent publications have provided insight into the antiinflammatory properties of FXR in atherosclerosis.
Bile salt signaling via TGR5 might regulate energy homeostasis, which could serve as an attractive target to increase
energy expenditure and weight loss. Interventions aiming to increase cholesterol turnover (eg, by bile salt sequestration)
significantly improve plasma lipid profiles and diminish atherosclerosis in animal models. Bile salt metabolism and bile
salt signaling pathways represent attractive therapeutic targets for the treatment of atherosclerosis. (Arterioscler
Thromb Vasc Biol. 2010;30:1519-1528.)
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Bile salts are crucial for the proper solubilization anduptake of dietary fats and fat-soluble vitamins in the
intestine. Bile salts are synthesized from cholesterol in
hepatocytes, and this conversion quantitatively represents
the major route for removal of cholesterol from the body.
Bile salts can also be synthesized from brain-derived
cerebrosterol1 or from oxysterols derived from other tis-
sues, but these appear to be minor pathways.2 It has been
demonstrated repeatedly that increasing the turnover of
bile salts has a beneficial effect on low-density lipoprotein
cholesterol (LDL-C) levels, a major risk factor for the
development of atherosclerosis and cardiovascular dis-
eases (CVD). Consequently, bile salt sequestrants (eg,
cholestyramine, colestipol, and colesevelam HCl) have
been successfully used to reduce LDL-C levels in patients
with hypercholesterolemia.
In addition to their role in absorption of dietary fats and
fat-soluble vitamins, bile salts have emerged as important
endocrine signaling molecules affecting multiple organs
beyond the organs constituting the enterohepatic tract. Bile
salts have been shown to signal via the farnesoid X
receptor (FXR/NR1H4) and the G protein-coupled bile
acid receptor 1 (TGR5/GPBAR1). However, (secondary)
bile salts have also been shown to activate the constitutive
androstane receptor,3 pregnane X receptor,4 and vitamin D
receptor.5
In addition to controlling their own metabolism, bile
salts influence cholesterol fluxes, inflammation, and vas-
cular tension. Moreover, bile salts are important modula-
tors of glucose, lipid, and energy metabolism. Bile salt
signaling pathways could therefore have profound effects
on the development of atherosclerosis. The use of geneti-
cally modified animal models has greatly contributed to
the understanding of the role of bile salt signaling in the
development of atherosclerosis. In contrast to humans,
however, mice transport the majority of plasma lipids in
high-density lipoprotein (HDL) particles, which makes
them less prone to atherosclerosis development. In addi-
tion, the bile salt composition differs considerably between
humans and mice. Besides cholate and chenodeoxycholate
(CDCA), present in both species, mice also produce
muricholates as primary bile salts. Moreover, whereas
mice conjugate the majority of their bile salts to taurine,6
human bile salts are conjugated predominantly to glycine.7
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This review is focused on evidence from basic and clinical
research investigating the contribution of bile salts and bile
salt-regulated signaling pathways on the development of
atherosclerosis.
Regulation of Bile Salt Synthesis
Cholesterol conversion to bile salts involves multiple
enzymatic conversions, sequentially carried out in the
endoplasmic reticulum, mitochondria, cytosol, and peroxi-
somes of hepatocytes. The end products of hepatic bile salt
synthesis are the primary bile salts cholate and CDCA,
synthesized in the neutral biosynthetic pathway. Rodents
synthesize limited amounts of CDCA but do form a series
of muricholates (, , ), ie, highly hydrophilic bile salt
species. CDCA can also be synthesized in the so-called
acidic biosynthetic pathway. Cholesterol 7-hydroxylase
(CYP7A1) is the first and rate-controlling enzyme in the
neutral pathway of bile salt synthesis, whereas sterol
27-hydroxylase (CYP27A1) has this function in the acidic
pathway. Sterol 12-hydroxylase (CYP8B1) determines the
ratio of cholate to CDCA synthesis in the neutral pathway.8
Upon conjugation with either taurine or glycine, bile salts
are secreted into bile. Structural modifications of bile salt
molecules by intestinal bacteria result in the formation of
secondary bile salts. Deoxycholic acid is the major sec-
ondary bile salt species. Bile salts are efficiently main-
tained in an enterohepatic circulation; 95% of biliary bile
salts are reabsorbed in the terminal ileum. A small fraction
of bile salts enters the colon to be converted to secondary
bile salts, which are partially reabsorbed. The fraction of
bile salts that finally escapes the enterohepatic circulation
is lost in the feces. This loss is completely compensated for
by de novo synthesis of bile salts from cholesterol.
Therefore, in steady state conditions, fecal excretion of
bile salts equals hepatic bile salt synthesis. The latter
contributes strongly to cholesterol turnover.9
Bile salts tightly regulate their own synthesis by acti-
vating FXR.10 FXR binds DNA mainly as a heterodimer
with the 9-cis-retinoic acid receptor (RXR/NR2B1). The
preferred DNA motifs for FXR/RXR are inverted repeat
elements separated by a spacing of a single nucleotide.11
Farnesol, a derivative of isoprenoid intermediates in the
cholesterol biosynthetic pathway, was first identified as
endogenous FXR ligand.12 Later studies identified bile
salts, in particular CDCA and deoxycholic acid, as the
most potent endogenous ligands for FXR.13,14 FXR-
dependent repression of bile salt synthesis was evidenced
by the use of Fxr/ mice, which are unable to reduce their
bile salt synthesis on bile salt feeding.15,16 Activated
hepatic FXR reduces the expression of CYP7A1 in a
pathway that requires activation of the small heterodimer
partner (SHP/NR0B2). SHP binds the nuclear liver recep-
tor homolog 1 (LRH-1/NR5A2) and blocks its transcrip-
tional activity.17 Initially, in vitro studies identified LRH-1
as a critical transcription factor for Cyp7a1.18,19 However,
results from in vivo studies questioned the regulatory role
of LRH-1 on Cyp7a1 transcription, as liver-specific Lrh-1
gene deletion did not alter the expression of Cyp7a1.20,21
Possibly, compensatory mechanisms regulate Cyp7a1 tran-
scription under conditions of Lrh-1 deficiency. Experimen-
tal proof for such a compensatory mechanism, however, is
still lacking. Clearly, many of the molecular details regard-
ing the bile salt-induced repression of Cyp7a1 repression
remain to be resolved.
FXR also regulates hepatic bile salt synthesis via an
autocrine mechanism. Activation of FXR in the distal
ileum induces the expression of Fgf15 (the mouse ortholog
of FGF19), which is subsequently thought to be released
into the portal bloodstream.22,23 Unlike for FGF19, detec-
tion of plasma FGF15 levels has yet to be accomplished.
The secreted FGF19/15 binds the FGFR4/klotho receptor
complex expressed on hepatocytes.22,24 This induces the
activation of various signal transduction routes, including
the jun N-terminal kinase/extracellular signal-regulated
kinase (JNK/ERK) pathway.23,25 Thus, the ability of FXR
to sense and act on bile salt concentration both in the liver
and in the terminal ileum allows for a potent and elegant
feedback machinery to tightly regulate bile salt synthesis
from distinct locations within the enterohepatic circula-
tion. Although FXR is considered the major regulator of
bile salt synthesis, other pathways likely are involved as
well.26 This, however, is beyond the scope of this review
and is discussed in detail elsewhere.27,28
Bile Salt Sequestrants
Stimulating fecal bile salt loss results in increased bile salt
synthesis from cholesterol in the liver. This leads to a
relative deprivation of hepatic microsomal cholesterol
content, which causes upregulation of the low-density
lipoprotein receptor (LDLR) as well as of 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase (HMGR).
Consequently, low-density lipoprotein (LDL) uptake from
plasma is increased, which leads to a reduction in plasma
LDL-C.29 –31 Expression levels of LDLR and HMGR are
under the control of sterol regulatory element binding
proteins (SREBPs) in a sterol-dependent manner, ie, low
sterol levels induce proteolytic cleavage of SREBP2 and
translocation into the nucleus, where it induces transcrip-
tion of its target genes.32 Via the reverse mechanism, high
hepatic cholesterol content leads to reduced expression of
LDLR in humans with CYP7A1 deficiency. These patients
have reduced clearance of very-low-density lipoprotein
(VLDL) particles and increased conversion of VLDL to
LDL. In addition, CYP7A1-deficient humans are resistant
to HMGR inhibitors, which was hypothesized to be due to
altered hepatic compartmentalization of CYP7A1 and
HMGR.33 Interestingly, Cyp7a1-null mice are normolipi-
demic and do not show hepatic cholesterol accumulation.34
Bile salt sequestrants reduce the reabsorption of bile
salts from the intestine and, hence, increase their excretion
into feces. Although bile salt sequestrants have been
shown to be effective in lowering LDL-C, modest in-
creases in plasma triglyceride levels have been repor-
ted.35,36 Pharmacological inhibition of the intestinal apical
sodium-dependent bile salt transporter (ASBT/ISBT/
SLC10A2) by SC-435 decreased LDL-C levels in athero-
sclerosis-susceptible Apoe/ mice.37 Interestingly, CDCA
increased LDLR expression levels and activity in vitro.38,39
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CDCA treatment in humans did not affect LDLR expres-
sion levels.40 The exact effect of CDCA treatment on the
expression of the LDLR is therefore yet to be defined. In
addition, this discrepancy indicates the importance of
crosstalk between intestine and liver. Consistent with the
role of FXR in repression of bile salt synthesis, treatment
of wild-type mice but not Fxr/ mice with the FXR
antagonist guggulsterone reduced hepatic cholesterol lev-
els.41 Nevertheless, concerns have been raised about the
specificity of this antagonist.42 Unfortunately, so far there
have been no reports on the existence of more specific
antagonists.
FXR and Lipid Metabolism
Elevated plasma LDL-C and triglyceride levels and re-
duced HDL cholesterol (HDL-C) levels are associated with
an increased risk to develop CVD. Bile salts exert a broad
regulatory role in systemic lipid metabolism via FXR.
Gallstone patients treated with CDCA showed decreased
plasma triglyceride levels and reduced VLDL produc-
tion.43 These results were confirmed in mouse studies
using synthetic FXR agonists.44,45 Both adenovirus-medi-
ated overexpression of FXR and treatment with the potent
FXR agonist GW4064 lowered plasma cholesterol levels in
mice.44 Moreover, the FXR agonist WAY-362450 was
shown to reduce serum cholesterol levels in mouse, rat,
and hamster.46 In addition, Fxr/ mice have increased
triglyceride and VLDL levels compared with their wild-
type littermates.15,47 Although initially Fxr/ mice were
reported to have increased plasma HDL-C levels only on
cholesterol feeding,15 later studies showed that Fxr/
mice have markedly elevated plasma HDL-C levels on
normal chow feeding.48,49 Thus, the expression and activity
of FXR seem to be associated with both anti- and proath-
erosclerotic lipid profile properties. Although the exact
molecular bases of these observations are yet to be
determined, an increasing body of evidence on the regu-
latory role of FXR in lipid metabolism is emerging. Bile
salts and synthetic FXR agonists were shown to repress the
transcription of Srebp-1c, a key regulator in triglyceride
synthesis.50 In agreement with this, Srebp-1c and fatty acid
synthase (Fas) expression levels were found to be induced
in Fxr/ mice.51 These data suggest that activated FXR
inhibits de novo lipogenesis in liver. Conversely, CDCA
treatment has been shown to reduce VLDL production
without significantly altering the expression levels of
Srebp-1c in fructose-fed hamsters.52 FXR-mediated
changes in Srebp-1c expression and activity might there-
fore be species-dependent and are possibly influenced by
diet. Indeed, intermediates of the pentose phosphate path-
way have been shown to upregulate Fxr expression in rat
hepatocytes, thereby providing evidence for a direct regu-
latory role of glucose on Fxr.53 Moreover, a direct role for
FXR in the expression of glucose-regulated genes has been
proposed. FXR activation has been shown to repress the
induction of the carbohydrate response element– binding
protein target genes Lpk, Acc-1, and S14 under high-
glucose conditions, whereas in Fxr/ mice, these genes
were induced under similar conditions.54 FXR-mediated
modification of carbohydrate response element– binding
protein target gene expression may thus alter lipogenic
substrate availability and add to the observed alterations in
hepatic triglyceride levels in Fxr/ mice.
Besides its effects on lipogenesis, FXR influences the
transcription of genes involved in lipoprotein metabolism.
FXR agonists induce the transcription of Apoc2, which
encodes the apolipoprotein that activates lipoprotein
lipase. In contrast, FXR agonists reduce the transcription
of Apoc3, a major constituent of VLDL that inhibits
lipoprotein lipase.55,56 In addition, the VLDL receptor
(VLDLR) was identified as an FXR target gene in the
liver.57 VLDLR is highly homologous to LDLR but is
present only in trace amounts in the liver. However, this
protein is highly expressed in skeletal muscle, heart,
adipose tissue, and macrophages, and its expression in
liver has been shown to complement the dyslipidemic
profile associated with familial hypercholesterolemia.58
FXR also negatively regulates the expression of microso-
mal triglyceride transfer protein and apolipoprotein B
(APOB).59 Microsomal triglyceride transfer protein is
involved in the transfer of triglycerides, cholesterol esters,
and phospholipids to newly synthesized APOB and thereby
plays a critical role in the assembly and secretion of VLDL
and chylomicrons. In human hepatic cells, FXR has been
shown to induce the expression of peroxisome proliferator-
receptor  (PPAR).60 Alterations of lipid metabolism in
humans could therefore involve FXR-mediated induction
of PPAR. Because the FXRE is not conserved in the
murine Ppar promoter, altered lipid profiles in Fxr/
mice are probably independent of FXR-mediated alter-
ations in Ppar.
Excess cholesterol is transported in HDL particles from
the periphery to the liver, where it is secreted into the bile,
either as free cholesterol61 or, upon conversion in the
hepatocyte, as bile salt. High HDL levels are generally
considered to be cardioprotective.62 Recent data, however,
underscore that it is not the HDL level per se but its
activity that determines the capacity to transport choles-
terol from peripheral tissues to the liver.63,64 The observa-
tion that bile salts and GW4064 reduced the expression of
APOA1, the major constituent of HDL,48 raises concerns
regarding the therapeutic value of FXR agonists. Consis-
tent with this finding, in vivo administration of GW4064
reduced the levels of HDL-C.50 This is consistent with the
observation that plasma HDL-C was increased in Fxr/
mice.48,49
FXR and Atherosclerosis
Currently, 3 studies have been published that assessed a
direct role for FXR in the initiation and progression of
atherosclerosis in mice.47,65,66 These studies were per-
formed in Fxr/ mice backcrossed on atherosclerosis-
susceptible mouse models, ie, Apoe/67 or Ldlr/
mice.68 Fxr/Apoe/ double knockout mice fed a high-
fat/high-cholesterol diet showed an increased atheroscle-
rotic lesion size compared with wild-type, Fxr/, and
Apoe/ mice.65 In agreement with this finding,
Fxr/Apoe/ double knockout mice showed a more
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atherogenic plasma lipid and lipoprotein profile, eg, in-
creased VLDL-C and LDL-C and reduced HDL-C levels.
Surprisingly, atherosclerosis was not detected in FXR/
mice fed the high-fat/high-cholesterol diet despite tremen-
dously increased plasma VLDL and LDL levels.65
In contrast, 2 other studies have reported that
Fxr/Apoe/ double knockout mice and Fxr/ Ldlr/
double knockout mice showed reduced atherosclerotic
lesion areas.47,66 In contrast, 1 study reported increased
LDL-C and triglycerides levels,66 whereas another re-
ported reduced LDL-C and increased triglyceride levels.47
The explanation for the observed discrepancies between
these studies is unclear, and they cannot be ascribed to
differences in plasma lipids. Thus, follow-up studies to
unravel these discrepancies are urgently needed. Despite
these discrepancies, studies on the activation of FXR
yielded consistent results. Recently, 2 articles addressing
the effects of FXR activation on atherosclerosis have been
published.45,69 In 1 study, Apoe/ mice were fed the
synthetic FXR agonist INT-47.69 Activation of FXR re-
duced aortic plaque formation with efficacy similar to that
of rosiglitazone, a potent and specific PPAR agonist with
established antiatherosclerotic effects.69 In another study,
both male and female Ldlr/ and Apoe/ mice were
shown to be protected against diet-induced aortic lesion
formation on treatment with the potent synthetic FXR
agonist WAY-362450.45 In addition, WAY-362450 pre-
vented increased plasma non-HDL-C levels and hepatic
cholesterol contents. Surprisingly, female but not male
mice had reduced aortic lesion formation. Although acti-
vation of FXR could have important therapeutic value in
atherosclerosis, the exact mechanisms involved are still
under debate. It is clear that data from animal models that
resemble the lipid profiles found in humans (majority of
cholesterol in LDL particles) are highly warranted. Guinea
pigs could be a suitable small animal model because these
animals have LDL and HDL profiles similar to those of
humans and are naturally prone to develop atherosclero-
sis.70 So far, gene knockout is unavailable in these models.
Nevertheless, alternative genetic strategies involving short
interfering RNA (siRNA)-mediated Fxr knockdown or
overexpression of Fxr are technically possible in guinea
pigs and could yield results with a higher correlative value
for the human situation. In addition, FXR activation
strategies such as bile salt or FXR agonist feeding in
guinea pigs could yield results that are indicative for FXR
activation in the human situation.
FXR in Vasculature
Recently, it was shown that FXR is expressed in vascular
smooth muscle cells (VSMC) of both normal and athero-
sclerotic blood vessels.71,72 In addition, FXR is expressed
in vascular endothelial cells.73 The use of specific FXR
agonists on arterial organ cultures and aortic endothelial
cell cultures revealed a role of FXR in these “nonclassical”
bile salt target tissues. Administration of GW4064 to organ
cultures from the main branches of the superior mesenteric
arteries of rabbits provided evidence for a role of FXR in
vascular contractility and endothelium-dependent relax-
ation.74 FXR activation impaired endothelium-dependent
relaxation due to a reduced sensitivity of smooth muscle to
nitric oxide (NO). In smooth muscle cells, NO induces
vasodilatation by increasing the synthesis of cGMP and
inhibition of Ca2 sensitization to contractile elements in
VSMC. Thus, FXR stimulation resulted in a hypertensive
phenotype, a well-known risk factor in the development of
atherosclerosis.75 On the other hand, GW4064 increased
eNOS mRNA and protein expression and NO production in
isolated endothelial cells, which is suggestive of a hypo-
tensive phenotype.76 It should be noted that the latter study
was performed in an endothelial cell line rather than in
organ cultures, the latter resembling the in vivo situation
more precisely. In line with a correlative hypotensive
phenotype, it was found that activation of FXR induced the
expression of dimethylarginine dimethylaminohydrolase-1
(DDAH1).77 DDAH1 degrades asymmetrical dimethylargi-
nine, which in turn is a potent nitric-oxide synthase
inhibitor. Activation of FXR also resulted in a repression
of endothelin 1 (EDN),73 a potent vasoconstrictive pep-
tide.78 Although these data are in agreement with the data
obtained from organ tissue cultures,74 it should be noted
that the administration of EDN to the GW4064-stimulated
in vitro cultured mesenteric arteries did not alter vascular
contractility.74 A study in rat aortic smooth muscle cells
also linked the activation of FXR to the regulation of
vascular tension. Activation of FXR induced vasoconstric-
tion via increased expression of the angiotensin type II
receptor (AT2R). AT2R is a key player in the renin-angio-
tensin system, which regulates blood pressure and inflam-
mation, 2 risk factors for the development of atheroscle-
rosis.79 In contrast, binding of the effector peptide
angiotensin II (AT2) to AT2R caused NO-mediated vaso-
dilatation.80 Despite these discrepancies, there is emerging
evidence that FXR influences vascular tension. Because all
of these studies were carried out in either rabbit superior
mesenteric arteries, rat endothelial cells or rat aortic
smooth muscle cells, the definite proof for the requirement
of FXR by means of FXR knockout could not be addressed.
Such knockout models are especially required to rule out
the possibility that some of the reported effects by the
agonist are attributable to off-target effects.
FXR has also been linked to the expression of proteo-
glycans.81 Proteoglycans are components of the extracel-
lular matrix that regulate cell proliferation, migration, and
the activation of growth factors and have been detected at
high concentrations in atherosclerotic lesions.82 Proteogly-
cans are thought to induce retention of lipoproteins within
the intima of the vessel wall and could therefore contribute
to atherosclerosis.83 An FXR-dependent upregulation of
decorin but not of other proteoglycans, such as versican or
biglycan, was found in VSMC.81 Interestingly, it was also
found that the adenoviral delivery of decorin attenuated
atherosclerosis development in Apoe/ mice.84 The pro-
tective properties of decorin on atherosclerosis suggest that
it does not act as a retentive molecule, and the interplay of
FXR and decorin in the regression of atherosclerosis
requires further investigation.
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Paraoxonase 1 (PON1) is produced by the liver and
secreted into plasma, where it is incorporated in HDL
particles.85 PON1 exhibits phospholipase A2 activity, which
might play a role in the inactivation of proatherogenic
inflammatory lipids produced by oxidative modification of
LDL. Interestingly, hepatic Pon1 transcription levels were
found to be repressed on bile salt feeding in mice in a
fibroblast growth factor 15/19 dependent manner.86 This
reduction was accompanied by a reduction of HDL-C levels,
which is in agreement with previously reported negative
correlations between FXR activation and HDL-C levels.50
FXR and Inflammation
Inflammation plays a role in almost every aspect of the
progression of atherosclerosis, eg, the progression of fatty
deposits to advanced lesions, plaque formation, and throm-
bosis.87 Recently, it was shown that inflammation impaired
reverse cholesterol transport, ie, cholesterol efflux from
lipid-laden foam cells onto circulating HDL for transport
to the liver for secretion into bile and feces.88 Several
studies assessed the impact of bile salt signaling on
inflammation in both vessel wall and liver. Activation of
FXR in VSMC was shown to inhibit the inflammatory
response and the migration of VSMC.71,89 In addition, FXR
activation in VSMC induced SHP expression and down-
regulation of COX-2 and iNOS, important contributors to
vascular inflammation and the migration of VSMC.89
Treatment of C57BL/6 mice with the FXR agonist WAY-
362450 attenuated lipopolysaccharide-induced serum amy-
loid P component and serum amyloid A3 mRNA levels in
the liver. This effect was not observed in Fxr/ mice.90
Loss of Fxr function was associated with increased inflam-
matory gene expression and extensive aortic plaque for-
mation in Apoe/ mice fed a high-fat, high-cholesterol
diet.65 These data provide new evidence for direct antiin-
flammatory properties of FXR in atherosclerosis.
Because Fxr/ mice display increased liver inflamma-
tion,91 FXR was suggested as a modulator of this process.
Nuclear factor B is considered a major regulator of the
inflammatory response and was shown to reduce the
expression of the nuclear steroid and xenobiotic receptor
(PXR).92 Interestingly, FXR activation antagonized nuclear
factor B signaling, which is suggestive of a crosstalk
between nuclear factor B and FXR.93 More evidence for
crosstalk between inflammatory pathways and FXR sig-
naling came from a study performed in macrophages in
which interferon- repressed Fxr gene expression.94 More-
over, expression levels of FXR and the FXR target genes
IBABP and SHP correlated with expression levels of the
chemokines interleukin 8 and macrophage inflammatory
protein-3 in Barrett epithelium, a condition in which bile
salts injure the esophageal mucosa because of chronic
gastroesophageal reflux. In vitro activation of FXR was
shown to induce recruitment of immune cells in Barrett
epithelium.95
FXR in Macrophages
A key event in atherosclerosis is apoptosis of lipid-
scavenging macrophages or foam cells resulting in the
formation of a necrotic core in an atheroma.96 Although it
was shown that FXR was not expressed in THP-1 cells
differentiated into macrophages and peritoneal macro-
phages,66,97 recent studies showed that Fxr is expressed in
RAW264.7 macrophages and in blood-derived macro-
phages.69 The contribution of FXR to gene regulation in
macrophages to atherosclerosis is still unclear. It was
found that Cd36 levels were reduced in macrophages
isolated from Fxr/ mice.66 CD36 is a member of the
class B scavenger receptor family of cell surface proteins
and is important for the uptake of oxidized LDL and free
fatty acids.98,99 In contrast, activation of FXR by INT-747
reduced the expression of Cd36 in Fxr-expressing macro-
phages.69 Furthermore, stimulation of FXR in macro-
phages attenuated lipopolysaccharide-induced generation
of the proatherosclerotic cytokines interleukin-1,
interleukin-6, and tumor necrosis factor . Importantly,
this effect was not seen in macrophages from Fxr/
mice.69 In addition, INT-747 could rescue the decrease of
Abca1 levels found in macrophages from Apoe/ mice.
ABCA1 acts together with ABCG1 to remove cholesterol
from macrophages and load it on to APO-A1 containing
HDL particles.100 Although these data suggest that FXR in
macrophages could play a role in “unloading” cholesterol
from these cells, the exact contribution of FXR in macro-
phages remains controversial, particularly as endogenous
ligands are unknown. Future studies using a conditional
knockout approach to selectively knock out Fxr in macro-
phages, as reported for Ppar,101 could reveal the impor-
tance of FXR in macrophages on atherosclerosis.
Bile Salt Signaling, Obesity, and
Energy Metabolism
Obesity is associated with an increased risk of developing
CVD. Excess adipose tissue can lead to dysregulation of
adipocytokine production. This can promote a state of
low-level systemic inflammation, which has been impli-
cated in the development of atherosclerosis.102 A role for
FXR in adipocyte function came from the observation that
Fxr/ mice have reduced fat cell size.103 In addition,
activation of FXR promotes adipocyte differentiation and
function in vivo and in vitro.104
The progression rate of atherosclerosis in obese people
can be significantly reduced by weight loss.105 Since bile
salts have emerged as important regulators of whole body
energy homeostasis, bile salt-activated signaling pathways
might serve as an attractive target to increase energy
expenditure and, hence, weight loss.106 Although in hu-
mans the role for bile salts as regulators of energy
metabolism is not fully defined, data from mouse studies
strongly suggest that bile salts could serve as important
modulators of energy metabolism. Fxr/ mice have an
accelerated entry into torpor on fasting and cold exposure
compared with wild-type littermates. A regulatory role for
FXR in thermogenesis was hypothesized to be due to low
triglyceride and glycogen stores in the white adipose tissue
and livers, respectively, of Fxr/ mice.107
Brown adipose tissue (BAT) is the main regulating
organ in energy expenditure in mice. However, both Fxr
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and Shp could not be detected in BAT,107,108 which would
exclude a direct role of the bile salt-FXR signaling
pathway in energy expenditure. Evidence for a role of bile
salts in energy metabolism via FXR-independent means
was reported by Watanabe et al, who observed that bile
salts could prevent development of obesity and insulin
resistance by increasing energy expenditure in BAT during
high-fat feeding in mice.108 Bile salts are suggested to
exert their action on energy metabolism via modulation of
local thyroid hormone production in brown adipose tissue
(rodents) and muscle (humans) via TGR5.109,110 Activation
of TGR5 by bile salts induces the conversion of inactive to
active thyroid hormones via type 1 and type 2 iodothyro-
nine deiodinase (D1 and D2).111 Thyroid hormones are
produced by the thyroid gland and act to increase meta-
bolic rate. TGR5 is expressed in a variety of tissues,
including muscle, central nervous system, BAT and gall-
bladder.108,110,112,113 Both male and female Tgr5/ mice
had a decreased bile salt pool size, suggestive of a
regulatory role of TGR5 in bile salt homeostasis. However,
in male mice, this was reflected only on the level of gene
expression. Additional effects of sex in Tgr5/ mice were
evident from observations that only female mice developed
accelerated obesity on high-fat feeding compared with
sex-matched wild-type littermates.114
In adult humans, muscle is considered the most impor-
tant thermogenic organ. Nevertheless, there is emerging
evidence that a substantial fraction of the adult human
population does posses active BAT.115 Interestingly, hu-
man myocytes were shown to express D2 and TGR5.108
In addition, thyroid hormones could be activated by D2 in
myocytes.116 Studies in which the role of bile salts in energy
metabolism in human muscle is assessed are still lacking. Bile
salts have been suggested as regulators of metabolic rate by
inducing the production of the incretin glucagon-like-peptide
1 (GLP-1) in a Tgr5-dependent manner in vitro.117 Recently,
it was shown that in vivo stimulation of TGR5 had beneficial
effects on glucose homeostasis and increased energy expen-
diture via, among others, increased incretin secretion in
mice.118 Incretins control initiation of satiety and glucose-
induced insulin secretion. These results suggest that bile salts
could serve as important regulators of energy expenditure.
Both FXR and TGR5 could serve as attractive targets for
weight loss, thereby reducing the development or progression
of atherosclerosis.
FXR Elsewhere
FXR is expressed in tissues not directly associated with
bile salt transport, synthesis, or metabolism, such as the
adrenals, kidney, and vasculature.71,119 Relatively high
FXR expression levels have been detected in the adrenal
cortex, as well as the renal tubules of the kidney.120 Little
is known about the function of FXR in these tissues. The
organic solute transporters  and  (OST and OST) are
direct FXR target genes in both the adrenal gland and the
kidney.119 OST and OST are transporters of bile salts
and conjugated steroids localized at basolateral mem-
branes in intestine and liver.121 These results are sugges-
Figure. This figure summarizes bile salt signaling pathways that may potentially intervene in the development of atherosclerosis. Bile
salts and bile salt signaling pathways (via FXR and TGR5) act on atherosclerosis in a multiorgan and multifactorial fashion. See text for
details.
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tive of a role for FXR in bile salt resorption in the kidney
and steroid homeostasis in the adrenal cortex. In line with
this, it was found that the enzyme 3-hydroxysteroid
dehydrogenase isomerase type II (HSD3B2), involved in
the synthesis of aldosterone and cortisol, is regulated by
FXR.122 Aldosterone is a mineralocorticoid synthesized in
the adrenal cortex from cholesterol and an indirect modu-
lator of vascular tension by modulating renal salt and water
retention. In addition, aldosterone has a direct effect on
vascular tension by binding mineralocortocoid receptors
on both endothelial and smooth muscle cells. Expression
of these receptors was increased in a hypertension-
susceptible rat model.123,124 The induction of HSD3B2
could therefore link adrenal FXR function to atheroscle-
rosis. In the vasculature, aldosterone impairs endothelium-
dependent relaxations, promotes inflammation, and stimu-
lates vascular remodeling.125 Interestingly, a possible
link between atherosclerosis and inflammation induced
by aldosterone was supported by the observation
that eplerenone, a selective blocker of mineralocortocoid
receptors, inhibits atherosclerosis in nonhuman
primates.126,127
Conclusion
Taken together, the data available to date suggest a
potential role of bile salts, the bile salt receptor FXR, and
possibly TGR5 in the progression and regression of ath-
erosclerosis. However, the molecular mechanisms and the
net effects of bile salts are yet to be determined. From the
current data, it is clear that the effects of bile salts and FXR
and TGR5 signaling pathways on atherosclerosis represent
a multiorgan and multifactorial interplay reaching beyond
the enterohepatic circulation (summarized in the Figure).
The preclinical phase of atherosclerosis in humans is
long; pathological changes in arteries can develop decades
before the disease presents clinically, and they are depen-
dent on a complex interaction between genetic and epige-
netic factors. Studies of early (plasma) markers of athero-
sclerosis and, especially, how these relate to early markers
for atherosclerosis in mice are therefore of great impor-
tance. Moreover, development of atherosclerosis in athero-
sclerosis-prone mouse models occurs predominantly in
females.128 This is in contrast to humans, where females
have a reduced risk of developing CVD, at least in the
premenopausal period.129 Therefore, caution should be
taken in extrapolating results obtained from mouse models
of atherosclerosis to humans. Humanized mouse models
such as the CETP.E3L mouse, which displays increased
LDL-C and triglyceride levels and decreased HDL-C
levels130 are prone to develop atherosclerosis on a
Western-type diet and are therefore valuable models to
study the effects of bile salt receptor signaling on hall-
marks of atherosclerosis. The use of tissue- and organ-
specific Fxr/ and Tgr5/ mice backcrossed to an
atherosclerosis-susceptible mouse strain may provide a
means to assess tissue-specific involvement of bile salt
receptors in the development or regression of atheroscle-
rosis. Alternatively, the use of short hairpin RNA ap-
proaches targeting Fxr or Tgr5 in animal models that
naturally match the HDL profile of humans, such as guinea
pigs, are a plausible strategy to verify the results obtained
using the atherosclerotic transgenic mouse models.
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